Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
JPMorgan Makes Stunning 10-Year Bitcoin Prediction

JPMorgan Makes Stunning 10-Year Bitcoin Prediction

UTodayUToday2026/10/21 13:27

In its new 2027 Long-Term Capital Market Assumptions report, the number one US bank puts Bitcoin's 10–15-year going-forward compound annual return at 10.0%. That is the best return of any major asset class in the table. Bitcoin's expected performance would be better than U.S. REITs (8.2%), U.S. small caps (7.7%), U.S. large caps (7.5%), emerging markets equities (7.1%), and even gold (5.5%).

The fact that Bitcoin is in the report in the report is noteworthy. This is the first time that JPMorgan has made a return range prediction for BTC in their long-term capital market assumptions. 

A capex boom 

JPMorgan says that with a global capex boom of $15 trillion (mainly the result of investment in AI and other technology), there will be higher growth, higher productivity, and robust returns for assets over the next decade. Additionally, the developed world will grow more, and bonds will have higher returns plus better opportunities for diversification.

$260K target

In a report dated September 17, JPMorgan analysts spearheaded by Nikolaos Panigirtzoglou say Bitcoin is still held less bullishly than gold by investors. Gold ETF outflows have been fully recovered from earlier in 2026, while Bitcoin ETF outflows have only been half recovered. But they say there is perhaps more potential upside to Bitcoin versus gold due to less hedging.

In February, JPMorgan also cited a $266,000 theoretical long-term value for Bitcoin, based on comparing Bitcoin to gold but adjusted for volatility.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks